Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06068192
Other study ID # RSP
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date January 1, 2024
Est. completion date October 1, 2026

Study information

Verified date September 2023
Source The First Hospital of Jilin University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

1) Establish a clinical data database for sepsis patients in the Emergency Department of the First Hospital of Jilin University. Describe the clinical data and prognosis of patients with simple systemic inflammatory response syndrome (common infection), pre sepsis, sepsis, and septic shock. 2) Explore the risk factors related to the progression of sepsis in patients in the early stages, as well as the risk factors related to the patient's prognosis. 3) Analyze the risk factors related to the prognosis of sepsis patients, and provide clinical basis for the treatment and long-term prognosis of sepsis patients. 4) Search for diagnostic biomarkers and prognostic serum biomarkers for patients with sepsis, sepsis, and septic shock.


Description:

The study site and population included patients with systemic inflammatory response syndrome caused by "infectious factors" who were admitted to the Emergency Department of the First Hospital of Jilin University from January 1, 2023 to December 31, 2027. The screening criteria for the study population were patients with "systemic inflammatory response syndrome" caused by sensory factors who were continuously registered and treated at the Emergency Department of the First Affiliated Hospital of Jilin University from January 1, 2023 to December 31, 2027. A. Inclusion criteria: 1) Age greater than or equal to 15 years old; 2) A patient who sought medical treatment at the Emergency Department of Jilin University First Hospital due to "systemic inflammatory response syndrome" (see relevant concepts and definitions in section 4.2 below). 3) Within 24 hours of seeking medical attention, evidence of "infection" can be clearly detected through imaging and laboratory examinations. Patients can be diagnosed and classified as at least one of the following conditions: respiratory system infection, digestive system infection, urinary system infection, blood borne infection, or skin soft tissue infection. B. Exclusion criteria: Patients with any of the following conditions need to be excluded from this study, including: 1) pregnant and lactating women; 2) Active pulmonary tuberculosis; 3) Patients who do not agree to participate in this study. The follow-up strategy is to follow up for 1 month and 3 months after discharge. Obtain patient information through telephone follow-up or on-site follow-up, with a loss of follow-up rate not exceeding 20%. The telephone follow-up includes the patient's daily discomfort symptoms, whether the infection has recurred, whether infection related symptoms have reappeared, if there is any organ damage upon discharge, it is necessary to inquire about re examination and recovery status, whether there are new diseases and treatment measures, and medication status; The follow-up at the hospital includes the patient's basic vital signs, blood routine, liver function, kidney function, cardiac ultrasound, and quality of life assessment. Please refer to the attachment for details< Table 3. Patient Follow up Information Collection Table>Follow up Time Range Follow up Method: 1 month before discharge, 1 week phone follow-up and/or hospital visit. 2 months after discharge, 1 week phone follow-up and/or hospital visit. Related concepts and definitions: A. Systemic Inflammatory Response Syndrome (SIRS) (refer to the 8th edition of Internal Medicine and the 2nd edition of Emergency Medicine), with the presence of corresponding injury factors, SIRS can be diagnosed if two or more of the following occur. 1) Body temperature>38 ℃ or<36 ℃. 2) Heart rate>90 beats per minute or hypotension (systolic blood pressure<90 mmHg, or a decrease of>40 mmHg from baseline). 3) Shortness of breath (>20 breaths/minute) or hyperventilation (PaCO2<32mmHg). 4) Peripheral blood white blood cell count greater than 12 × 109/L or less than 4 × 109/L, or immature white blood cells greater than 10%, but other reasons that can cause the aforementioned acute abnormal changes should be ruled out. B. Grouping of SIRS patients: The diagnostic criteria in this section refer to the 2021 Surviving sepsis campaign guidelines


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 500
Est. completion date October 1, 2026
Est. primary completion date October 1, 2026
Accepts healthy volunteers
Gender All
Age group 15 Years and older
Eligibility Inclusion Criteria: 1. Age greater than or equal to 15 years old; 2) A patient who sought medical treatment at the Emergency Department of Jilin University First Hospital due to "systemic inflammatory response syndrome" (see relevant concepts and definitions in section 4.2 below). 3) Within 24 hours of seeking medical attention, evidence of "infection" can be clearly detected through imaging and laboratory examinations. Patients can be diagnosed and classified as at least one of the following conditions: respiratory system infection, digestive system infection, urinary system infection, blood borne infection, or skin soft tissue infection. Exclusion Criteria: 1. pregnant and lactating women; 2) Active pulmonary tuberculosis; 3) Patients who do not agree to participate in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
no intervention
no intervention

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
The First Hospital of Jilin University

Outcome

Type Measure Description Time frame Safety issue
Primary The patient dies within 28 days after hospitalization The patient dies within 28 days after hospitalization within 28 days after hospitalization
Primary The patient does not die within 28 days after hospitalization The patient does not die within 28 days after hospitalization within 28 days after hospitalization
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3